Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of Etrasimod in Moderately to Severely Active Ulcerative Colitis
2018-003987-29Phase 3Active
- Sponsor
- Pfizer
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of etrasimod in autoimmune colitis, sponsored by Pfizer. Primary endpoint: Incidence of treatment-emergent adverse events and serious adverse events. Started Apr 2019; status: active.
02
Drugs
etrasimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2018-003987-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003987-29.